HRS9531
Hengrui Pharma's dual GIP/GLP-1 agonist — part of China's increasingly competitive incretin program.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
A Chinese-developed dual incretin agonist with Phase 2 weight-loss data in the same range as tirzepatide. Part of a wave of Chinese metabolic-disease pharmacology entering global discussion.
- Class
- Dual GIP/GLP-1 receptor agonist
- Sponsor
- Jiangsu Hengrui Pharmaceuticals
- Stage
- Phase 2/3 in China; earlier-stage globally
- Lead use case
- Obesity and type 2 diabetes
What it is
HRS9531 is a synthetic peptide dual agonist of the GIP and GLP-1 receptors developed by Jiangsu Hengrui Pharmaceuticals. It is part of the broader emergence of Chinese metabolic-disease pharmacology programs that have produced mazdutide, ecnoglutide, and several other incretin candidates.
Current research status
Phase 2 obesity trial results from China showed weight-loss magnitudes in the same range as tirzepatide at comparable timepoints. The Phase 3 program is advancing in China; global development partnerships are part of the company's reported strategy.
Mechanistic rationale
Standard dual GIP/GLP-1 receptor agonism — the same mechanism as tirzepatide. The GLP-1 arm contributes appetite suppression, slowed gastric emptying, and glucose-dependent insulin release; the GIP arm contributes additional adipose-tissue and central appetite effects. The molecular tuning of the two receptor affinities is the differentiation among compounds in this class.
Available evidence
Chinese Phase 2 obesity trial — Reported approximately 16-20% weight loss at higher doses over 24-36 weeks in obese adults without diabetes, supporting Phase 3 advancement.[1]
Why it's interesting
The Chinese metabolic-disease pharmacology landscape has matured considerably and is increasingly producing molecules competitive with the lead Western programs. HRS9531, mazdutide, and ecnoglutide collectively suggest the next decade of obesity therapeutics will be more globally distributed than the past decade has been. From a pure-pharmacology standpoint, HRS9531's results in the same range as tirzepatide indicate the GIP/GLP-1 dual-agonist class is reproducible across molecular variants.
Limitations & risks
Western regulatory pathways for HRS9531 are not as advanced as the Chinese pathway. Differences in trial-design conventions, regulatory standards, and post-approval surveillance between China and Western jurisdictions are part of how the molecule will be evaluated as it pursues broader markets. Direct head-to-head data with tirzepatide is not available.
Community discussion notes
Part of a broader pattern in 2024-2025 of Chinese metabolic compounds entering Reddit and biohacker discussion as alternatives to Western brand-name products, often via grey-market sourcing. The compound itself is investigational; what's sold as HRS9531 in research-peptide channels has not been independently verified.
The takeaway
HRS9531 represents the increasing globalization of obesity-therapeutic development. The molecule itself is a credible dual-agonist candidate; the broader signal — that competitive incretin programs are now developing across multiple regions — is likely to shape access and pricing dynamics for the next decade.
References
- Hengrui Pharmaceuticals. HRS9531 Phase 2 obesity trial results (corporate disclosure; peer-reviewed publication anticipated). https://pubmed.ncbi.nlm.nih.gov/?term=HRS9531
- Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes. Diabetes Ther. 2021;12(1):143-157. https://pubmed.ncbi.nlm.nih.gov/33325008/